New treatments for BRAF V600 positive melanoma

Trametinib (Mekinist) and cobimetinib (Cotellic) are new targeted treatments for patients with unresectable or metastatic melanoma who have a BRAF V600 mutation

Mekinist can be given as monotherapy or in combination with the BRAF inhibitor dabrafenib (Tafinlar), and Cotellic is indicated in combination with the BRAF inhibitor vemurafenib (Zelboraf).

The two drugs are reversible inhibitors of mitogen-activated extracellular signal regulated kinases MEK1 and MEK2, components of the Ras/Raf/MEK/ERK signalling cascade. This pathway can be activated by mutated forms of BRAF

Trametinib/dabrafenib versus dabrafenib alone

In the phase III, randomised, double-blind COMBI-d study (n = 423), median progression-free survival (primary endpoint) was significantly greater in patients taking dabrafenib plus trametinib than in those receiving dabrafenib plus placebo (9.3 months versus 8.8 months, p = 0.03), as was overall survival (25.1 months versus 18.7 months, p = 0.0107).

Trametinib/dabrafenib versus vemurafenib

The open-label COMBI-v study compared trametinib/dabrafenib to monotherapy with vemurafenib (n = 704). Overall survival was significantly greater with the combination than with vemurafenib alone, at 72% and 65% in the two groups, respectively (p = 0.005). 

Cobimetinib/vemurafenib versus vemurafenib alone

In the phase III coBRIM study in 495 previously untreated patients, median progression-free survival was 9.9 months among those who received vemurafenib and cobimetinib, compared with 6.2 months in those who received vemurafenib and placebo (p <0.001). 

Adverse events

The most common adverse events seen with trametinib in monotherapy and combination therapy are fatigue, diarrhoea and nausea. Ocular and skin disorders are also common. 

Left ventricular ejection fraction should be monitored in all patients before and during treatment, because it can be decreased by trametinib. 

In trials of cobimetinib, serous retinopathy occurred in more than 10% of patients treated with the drug. Patients reporting new or worsening visual disturbances should be referred for ophthalmological examination. Treatment discontinuation, interruption or dose reduction should be considered if a diagnosis of serous retinopathy is confirmed. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases